Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS) (TARGET 2)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Alabama
-
Anniston、Alabama、美国、36207
-
Birmingham、Alabama、美国、35205
-
Huntsville、Alabama、美国、35801
-
-
Arizona
-
Tempe、Arizona、美国、85282
-
-
California
-
Anaheim、California、美国、92801
-
Carmichael、California、美国、95608
-
Chula Vista、California、美国、91910
-
Concord、California、美国、94520
-
Garden Grove、California、美国、92840
-
Laguna Hills、California、美国、92653
-
Lakewood、California、美国、90712
-
Los Angeles、California、美国、90048
-
Monterey、California、美国、93940
-
Orange、California、美国、92868
-
Roseville、California、美国、95661
-
San Carlos、California、美国、94070
-
San Francisco、California、美国、94117
-
-
Connecticut
-
Bristol、Connecticut、美国、06010
-
Hamden、Connecticut、美国、06518
-
-
Delaware
-
Newark、Delaware、美国、19713
-
-
Florida
-
Boca Raton、Florida、美国、33486
-
Hollywood、Florida、美国、33021
-
Largo、Florida、美国、33777
-
New Port Richey、Florida、美国、34655
-
New Smyrna Beach、Florida、美国、32168
-
Port Orange、Florida、美国、32127
-
Saint Petersburg、Florida、美国、33709
-
Tampa、Florida、美国、33607
-
Zephyrhills、Florida、美国、33542
-
-
Georgia
-
Atlanta、Georgia、美国、30342
-
Macon、Georgia、美国、31201
-
-
Indiana
-
Elkhart、Indiana、美国、46514
-
-
Kansas
-
Kansas City、Kansas、美国、66160
-
Topeka、Kansas、美国、66606
-
-
Kentucky
-
Bowling Green、Kentucky、美国、42104
-
-
Louisiana
-
Metairie、Louisiana、美国、70006
-
Monroe、Louisiana、美国、71201
-
-
Maryland
-
Baltimore、Maryland、美国、21229
-
Elkridge、Maryland、美国、21075
-
-
Massachusetts
-
Wellesley、Massachusetts、美国、02481
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
-
Troy、Michigan、美国、48098
-
Wyoming、Michigan、美国、49519
-
-
Missouri
-
Mexico、Missouri、美国、65265
-
-
New Jersey
-
Sicklerville、New Jersey、美国、08081
-
Voorhees、New Jersey、美国、08043
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87102
-
-
New York
-
Great Neck、New York、美国、11021
-
Mineola、New York、美国、11501
-
New York、New York、美国、10016
-
North Massapequa、New York、美国、11758
-
Pomona、New York、美国、10970
-
Stony Brook、New York、美国、11790
-
-
North Carolina
-
Boone、North Carolina、美国、28607
-
Chapel Hill、North Carolina、美国、27514
-
Charlotte、North Carolina、美国、28209
-
Greensboro、North Carolina、美国、27408
-
Greensboro、North Carolina、美国、27403
-
New Bern、North Carolina、美国、28562
-
Wilmington、North Carolina、美国、28401
-
Winston-Salem、North Carolina、美国、27103
-
-
Ohio
-
Canton、Ohio、美国、44718
-
Cincinnati、Ohio、美国、45242
-
Dayton、Ohio、美国、45415
-
-
Pennsylvania
-
Downingtown、Pennsylvania、美国、19335
-
Newtown、Pennsylvania、美国、18940
-
Pittsburgh、Pennsylvania、美国、15206
-
Sayre、Pennsylvania、美国、18840
-
-
South Carolina
-
Anderson、South Carolina、美国、29621
-
Columbia、South Carolina、美国、29203
-
-
Tennessee
-
Bristol、Tennessee、美国、37620
-
Chattanooga、Tennessee、美国、37421
-
Franklin、Tennessee、美国、37067
-
Germantown、Tennessee、美国、38138
-
Jackson、Tennessee、美国、38301
-
Kingsport、Tennessee、美国、37660
-
-
Texas
-
El Paso、Texas、美国、79902
-
Houston、Texas、美国、77024
-
Lewisville、Texas、美国、75057
-
Plano、Texas、美国、75075
-
San Antonio、Texas、美国、78229
-
-
Utah
-
Salt Lake City、Utah、美国、84107
-
-
Vermont
-
Burlington、Vermont、美国、05401
-
-
Virginia
-
Chesapeake、Virginia、美国、23320
-
Fairfax、Virginia、美国、22031
-
-
Washington
-
Spokane、Washington、美国、99208
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
-
Milwaukee、Wisconsin、美国、53215
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Confirmed IBS diagnosis per Rome II criteria for diagnosis of IBS.
- Colonoscopy within 2 years as part of IBS diagnostic evaluation.
- Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.
Exclusion Criteria:
- Symptoms of constipation.
- History of other gastrointestinal diseases.
- Type 1 or 2 diabetes.
- Lactose intolerance not controlled by lactose-free diet.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
安慰剂比较:Placebo
Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
|
|
实验性的:Rifaximin
Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
大体时间:4 weeks
|
The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? [Yes/No]" |
4 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)
大体时间:4 weeks
|
The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? [Yes/No]." |
4 weeks
|
合作者和调查者
调查人员
- 研究主任:Enoch Bortey、Bausch Health Americas, Inc.
出版物和有用的链接
一般刊物
- Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.
- Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014 May;39(10):1161-8. doi: 10.1111/apt.12735. Epub 2014 Apr 3.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
安慰剂的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的